ETON
ETON
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$125K
Insider Sales
12
$35.29M
Total Volume
$35.42M
13 transactions
Net Activity
$35.17M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Brynjelsen Sean
Pres, CEO
$13.51M total
Opaleye Management Inc.
10%
$5.96M total
Krempa David
Chief Business Officer
$5.36M total
Casamento Charles J
Dir
$5.35M total
Maier Paul V
Dir
$2.95M total
Quick Actions
ETON has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. ETON ranks #183 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at ETON (ETON) engaged in a total of 13 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 12 were sales. The total volume of insider trading reached $35.42M.
The net insider activity for ETON shows a net selling bias of $35.17M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Brynjelsen Sean (Pres, CEO), who traded 100.0K shares valued at $6.09M on Aug 19, 2026.
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
Why Eton Pharmaceuticals Is Top of the Class Today
Eton Pharma jumps after Q3 beat and guidance hike
Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High
ETON - Eton Pharmaceuticals Inc Stock Price and Quote
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
FAQs About ETON Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ETON.